Bronstein, Gewirtz & Grossman LLC announces that Caribou Biosciences, Inc. investors with significant losses have the opportunity to file a class action lawsuit against Investing.com
New York, New York–(Newsfile Corp. – January 05, 2025) – Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, informs investors that a class action lawsuit has been filed against Caribou Biosciences, Inc. (” Caribou” or the “Company”) (NASDAQ: CRBU) and certain of its officers.
Class definition
This action seeks damages against the defendants for alleged violations of federal securities laws on behalf of all persons and entities who purchased or otherwise acquired Caribou securities between July 14, 2023 and July 16, 2024, both dates inclusive ( “Class Period” ). Such investors are encouraged to join the case by visiting the company’s website: bgandg.com/CRBU.
Details of the case
The complaint alleges that during the Lecture Period, the defendants made materially false and misleading statements regarding the Company’s business, operations and prospects. Specifically, the lawsuit alleges that the defendants made false and/or misleading statements and/or failed to disclose that they: (1) overestimated the safety, efficacy, and durability of CB-010 relative to approved autologous CAR-T cell therapies in the treatment of patients with /r B-NHL and/or LBCL, as well as CB-010’s overall clinical results and commercial prospects; (2) Caribou was exposed to a significant risk of not having sufficient cash, liquidity and/or other capital to fund its ongoing business operations, including preclinical research activities related to the allogeneic CAR-NK platform; (3) all of the foregoing could have a material adverse effect on Caribou’s business and operations; and (4) as a result, the defendant’s public statements were materially false and misleading at all relevant times.
What’s next?
A class action lawsuit has already been filed. If you would like to review a copy of the complaint, you may visit the company’s website: bgandg.com/CRBU. or you can contact Peretz Bronstein, Esq. or his client relationship manager, Nathan Miller, of Bronstein, Gewirtz & Grossman, LLC at 332-239-2660. If you suffered a loss in Caribou, you have until February 24, 2025 to request that the court appoint you as the lead plaintiff. Your ability to participate in the recovery does not require you to be the lead plaintiff.
There is no cost to you
We represent investors in contingent fee class actions. This means that we will ask the court to reimburse us for out-of-pocket costs and attorneys’ fees, usually a percentage of the total recovery, only if we are successful.
Why Bronstein, Gewirtz & Grossman
Bronstein, Gewirtz & Grossman, LLC is a nationally recognized firm that represents investors in securities class actions and equity derivatives. Our company has recovered hundreds of millions of dollars for investors across the country.
To view the original version of this press release, visit https://www.newsfilecorp.com/release/235262
